Evaluation of Clinical Utility and Validation of Gene Signatures in Clinical Trials

With the advent of the targeted therapy era, molecular signatures are becoming increasingly important for anticipating the prognosis of individual patients (prognostic biomarkers) or for predicting how individual patients will respond to speciˆc treatments (predictive biomarkers, more generally called effect modiŽers).